Journal
INTERNAL MEDICINE
Volume 51, Issue 15, Pages 2041-2044Publisher
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.51.7592
Keywords
dipeptidyl peptidase (DPP)-4 inhibitor; rheumatoid arthritis; human leukocyte antigen (HLA)
Categories
Ask authors/readers for more resources
A dipeptidyl peptidase (DPP)-4 inhibitor, commonly used to treat patients with type 2 diabetes, has caused concern because of immune system side effects. We report a 48-year-old woman with type 2 diabetes who was diagnosed with rheumatoid arthritis (RA) after continued polyarthritis and an increase in rheumatoid factor up to 86 IU/mL after three months of treatment with sitagliptin, a DPP-4 inhibitor. The shared epitope (SE)-containing human leukocyte antigen (HLA)-DRB1 alleles, which are important predisposing factors for RA, were positive. RA might have been triggered by sitagliptin due to a predisposing condition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available